Montelukast dose selection in children ages 2 to 5 years: Comparison of population pharmacokinetics between children and adults

Journal of Clinical Pharmacology

Volumn 41, Issue 6, 2001, Pages 612-619

  Knorr, B ^a   Nguyen, H H ^a   Kearns, G L ^a   Villaran, C ^a   Boza, M L ^a   Reiss, T F ^a   Rogers, J D ^a   Zhang, J ^a   Larson, P ^a   Spielberg, S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONTELUKAST; PEPTIDOLEUKOTRIENE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CHEWABLE TABLET; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PRESCHOOL CHILD; UPPER RESPIRATORY TRACT INFECTION;

ACETATES; ADULT; ANTI-ASTHMATIC AGENTS; AREA UNDER CURVE; ASTHMA; CHILD; CHILD, PRESCHOOL; DOSAGE FORMS; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; QUINOLINES;

EID: 17844373539     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122010492     Document Type: Article

References (36)

1. Childhood- versus adult-onset asthma
2. Modern treatment of asthma in children
3. New insights into the understanding of asthma
4. Ultrastructure of airways in children with asthma
5. Comparison of maximal airway narrowing to methacholine between children and adults
6. Leukotrienes and histamine mediate IgE-dependent contractions of human bronchi: Pharmacological evidence obtained with tissues from asthmatic and non-asthmatic subjects
7. Cysteinyl leukotrienes in asthma: Old mediators up to new tricks
8. The role of leukotrienes in asthma and allergic rhinitis
9. Release of leukotrienes in patients with bronchial asthma
10. Bronchoconstrictor effects of leukotriene C in humans
11. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge
12. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a CysLT1 receptor antagonist
13. Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma
14. Leukotrienes and other products of the 5-lipoxygenase pathway
15. Dose-dependent mediation of leukotriene D4-induced airway microvascular leakage and bronchoconstriction in the guinea pig
16. Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma
17. Leukotriene antagonists and synthesis inhibitors: New directions in asthma therapy
18. Pharmacology of montelukast sodium (Singulair™), a potent and selective leukotriene D4 receptor antagonist
19. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist
20. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma
21. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma, a randomized, controlled trial
22. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: A multicenter, randomized, double-blind trial
23. Montelukast for chronic asthma in 6- to 14-year-old children
24. Doserelated protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval
25. Diurnal variation of asthma
26. Montelukast dose selection in 6- to 14-year-olds: Comparison of single-dose pharmacokinetics in children and adults
27. Use of the population one-compartment model to design a study to best estimate the AUC with limited number of time points per patient
28. Determination of MK-0476 in human plasma by liquid chromatography
29. Specific requirements on content and format of labeling for human prescription drugs: Revision of "pediatric use" subsection in the labeling: Final rule
30. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma
31. Statistical considerations in pharmacokinetic study design
32. Role of population pharmacokinetics in drug development
33. Single dose pharmacokinetics, safety, and tolerability of MK-0476, a new leukotriene D4-receptor antagonist, in healthy volunteers
34. Evaluation of the safety profile of montelukast (MK-0476) in pediatric patients aged 2 to 5 years
35. Montelukast (MK-0476) improves asthma over a 3 month treatment period in 2- to 5-year olds